<DOC>
	<DOCNO>NCT01622075</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety successful interventional therapy unblock blood vessel maintain treatment coronary in-stent restenosis paclitaxel -eluting PTCA- balloon catheter ( 3μg/mm2 balloon surface area ) versus paclitaxel-eluting stent Taxus® Liberte , reference diameter coronary artery stenosis 2.5mm-4.0mm length ≤30mm .</brief_summary>
	<brief_title>A Safety Efficacy Study Paclitaxel-eluting Balloon Paclitaxel-eluting Stent</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Related patient Patients stable angina , unstable angina , old myocardial infarction proven asymptomatic ischemia Restenosis first stent implant Patients receive kind coronary revascularization ( include balloon angioplasty , stent implantation coronary artery bypass graft ) Patient age 1880 ( include 18 80 ) Female patient childbearing age study period shall pregnant protocol pregnant , suggest patient shall take sufficient contraception measure till ( include ) followup visit month 9 Patients agree accept angiography followup visit month 9 Patients agree accept clinical visit Day 30 , Month 6 Month 12 Patients understand study objective psychologically linguistically show sufficient compliance study protocol . Patients present acceptance risk benefit describe informed consent form . 2 . Related lesion Drugeluting stent restenosis : Type Mehran I , Type II Type III ; reference blood vessel diameter 2.5 mm4.0 mm , length ≤30mm Before surgery , stenosis diameter must ≥70 % ≥50 % accompany ischemia The distance lesion require interventional therapy target lesion must &gt; 10mm In stent group , two paclitaxel drug stent permit implanted series 1 . Related patient Patients myocardial infarction within one week Patients severe congestive heart failure NYHA IV severe heart failure Patients severe valvular heart disease Female patient pregnancy lactation Patients life expectancy exceed 1 year factor cause difficult clinical followup visit Patients hemorrhagic tendency , prohibit take anticoagulant antiplatelet drug Patients stroke within 6 month surgery Patients take part clinical test Existing sever renal failure ( GFR &lt; 30ml/min ) history , meeting condition angiography Patients cardiac transplantation Patients include reason investigator 2 . Related lesion Evidence extensive thrombus target blood vessel intervention Percutaneous coronary intervention many instent restenosis lesion artery 3vessel disease need intervented In bifurcation lesion , branch open blood vessel diameter ≥2.5mm Percutaneous coronary intervention venous graft Entire shut Grade TIMI 0 blood flow ( Type Mehran IV stenosis ) Open lesion leave primary within 2mm 3 . Related concomitant therapy Patients tolerate aspirin and/or clopidogrel , patient history neutrocytopenia thrombocytopenia , patient severe hypohepatia prohibit take clopidogrel Patients know allergic paclitaxel Patients history leucopenia ( numeration leukocytes &lt; 3x109/L , exceed 3 day ) , neutrocytopenia ( ANC &lt; 1000 neutrocytes/mm3 , exceed 3 day ) thrombocytopenia ( &lt; 100,000 platelets/mm3 Patients history peptic ulcer gastrointestinal hemorrhage past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>